This is the authors' abstract. We don't add key points for this paper.
More than 100 million administrations worldwide have shown gadobutrol's well-established benefit-risk profile in any approved indication and populations.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Endrikat et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: